Actively Recruiting
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
Led by LMU Klinikum · Updated on 2023-11-21
156
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
Sponsors
L
LMU Klinikum
Lead Sponsor
G
German Research Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Aerobic endurance training has shown positive effects on symptoms, cognition, daily functioning, and the structure of the hippocampus in patients with schizophrenia. The study investigates genetic and epigenetic influences on neuroplastic changes following three months of endurance training. A control group performs flexibility, strength, and balance training. The main objective is to examine the association between a genetic risk score for schizophrenia and volume increase in the CA4/DG region of the hippocampus. Additional goals include examining changes in synapses, brain structure, function, and metabolism, as well as clinical symptoms and cognitive performance.
CONDITIONS
Official Title
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent for voluntary study participation.
- Diagnosis of schizophrenic psychosis according to ICD10 and DSM V.
- Positive And Negative Syndrome Scale (PANSS) total score 75 before the start of the intervention.
- Reliable contraception in women of childbearing age.
- Treatment with individualized antipsychotic medication according to valid guidelines, with stable dose for at least 2 weeks before inclusion.
- Allowed treatment with one or two antipsychotic substances, including depot medication.
- Additional use of low- and medium-potency antipsychotics on demand allowed if daily dosage does not exceed 150 CPZ units.
You will not qualify if you...
- Lack of reliability and sanity as examined by an independent psychiatrist.
- Positive urine drug screen for illicit drugs (except benzodiazepines).
- Acute suicide risk.
- Other relevant psychiatric axis-I disorders according to Mini International Neuropsychiatric Interview (MINI).
- Other relevant neurological or other disorders.
- Pregnancy or lactation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
LMU Klinikum
Munich, Bavaria, Germany, 80336
Actively Recruiting
Research Team
I
Isabel Maurus, Dr.
CONTACT
L
Lukas Roell, M.Sc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here